Study of Antidiabetic Properties of Berberis asiatica and Withania somnifera in Streptozotocin-Nicotinamide-Induced Type II Diabetes Mellitus in Wistar Rats

被引:2
|
作者
Tiwari, Devkumar D. [1 ]
Thorat, Vandana M. [1 ]
Pakale, Prathamesh, V [1 ]
Patil, Sarika J. [1 ]
机构
[1] Krishna Vishwa Vidyapeeth, Dept Pharmacol, Satara, India
关键词
combination effect; ethanolic plant extract; animal study; diabetes type 2; herbal drugs; PROTEIN-KINASE; PLANT; ROOT; ASHWAGANDHA;
D O I
10.7759/cureus.64379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aim Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. Although current antidiabetic drugs are highly effective, they are associated with various adverse drug reactions, including lifethreatening hypoglycemia, skin rashes, and gastrointestinal intolerance, in addition to being costly. This animal-based experimental study aims to develop a herbal alternative or adjuvant to current antidiabetic drugs using Berberis asiatica ( BA ) and Withania somnifera ( WS ), which could potentially have fewer adverse drug reactions and reduce the required dose of existing antidiabetic medications. Material and methods Seventy-eight adult albino Wistar rats weighing between 150 and 250 g were used for the study. Diabete smellitus (DM) was induced by intraperitoneal (i.p) injections of streptozotocin (STZ) (65 mg/kg) 15 minutes after nicotinamide (NIC) (110 mg/kg) administration. As the diabetes was confirmed (blood glucose level >250 mg/dL), rats were divided into 13 different groups mentioned. The standard antidiabetic drugs(metformin [MET] and glimepiride [GLI]) and polyherbal combinations (PHC) (BA + WS) were administeredorally, individually (WS and BA), and in combination (BA + WS). Blood samples were collected for biochemical analysis using the tail vein prick method. The study is based on a total of 13 groups, six rats in each group. Groups 1 and 2 (normal control [NC] anddiabetic control [DC]) received distilled water at a dose of 10 mL/kg orally for 28 days. Groups 3-5 (BA 250,500, and 1000) received dried ethanolic root extract of BA at a dose of 250, 500, and 1000 mg/kg orally,respectively, for 28 days. Groups 6-8 (WS 250, 500, and 1000) received dried ethanolic root extract of WS at adose of 250, 500, and 1000 mg/kg orally, respectively, for 28 days. Groups 9-11 (PHC 250, 500, and 1000)received dried ethanolic root extract of BA + WS at a dose of 250, 500, and 1000 mg/kg orally, respectively,for 28 days. Groups 12 and 13 (MET and GLI) received standard drugs MET and GLI at a dose of 250 and 10mg/kg orally, respectively, for 28 days. Results The dried ethanolic root extract of medicinal herbal plants BA and WS and their combination exhibited significant antidiabetic efficacy. PHC has been shown to have a superior antidiabetic effect than individuals. PHC 500 and 1000 showed blood glucose levels similar to those of the GLI group (P < 0.05). Additionally, PHC 1000 showed blood glucose levels similar to those of the MET group (P < 0.05). Conclusion Our results indicate that both BA and WS possess hypoglycemic activity, and their combination also has a synergistic antidiabetic effect compared to the individual extract. These findings are promising in developing new safe and cost-effective herbal combinations as alternatives or additives to currently used synthetic antidiabetic drugs.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [21] Naringin ameliorates cognitive impairment streptozotocin/nicotinamide induced type 2 diabetes in Wistar rats
    Oyindamola, Abiodun O.
    Adewale, Bakre G.
    Christiana, Adekoya T.
    Adebola, Kazeem, I
    Tolulope, Oke A.
    Tejumade, Ujomu S.
    PHYSIOLOGY AND PHARMACOLOGY, 2022, 26 (01): : 20 - 29
  • [23] Antidiabetic activity of aqueous root extract of Ichnocarpus frutescens in streptozotocin-nicotinamide induced type-II diabetes in rats
    Barik, Rakesh
    Jain, Sanjay
    Qwatra, Deep
    Joshi, Amit
    Tripathi, Girraj Sharan
    Goyal, Ravi
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 (01) : 19 - 22
  • [24] Effect of madecassoside in reducing oxidative stress and blood glucose in streptozotocin-nicotinamide-induced diabetes in rats
    Tan, Swee Ching
    Rajendran, Ramkumar
    Bhattamisra, Subrat Kumar
    Krishnappa, Purushotham
    Davamani, Fabian
    Chitra, Ebenezer
    Ambu, Stephen
    Furman, Brian
    Candasamy, Mayuren
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2023, 75 (08) : 1034 - 1045
  • [25] Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice
    Tahara, Atsuo
    Matsuyama-Yokono, Akiko
    Shibasaki, Masayuki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 655 (1-3) : 108 - 116
  • [26] Antidiabetic effect of fucoxanthin extracted from Sargassum angustifolium on streptozotocin-nicotinamide-induced type 2 diabetic mice
    Oliyaei, Najme
    Moosavi-Nasab, Marzieh
    Tamaddon, Ali Mohammad
    Tanideh, Nader
    FOOD SCIENCE & NUTRITION, 2021, 9 (07): : 3521 - 3529
  • [27] Distribution of interstitial cells of Cajal and nerve fibers in rat stomach in streptozotocin-nicotinamide-induced diabetes mellitus
    Velickov, Aleksandra I.
    Petrovic, Vladimir
    Djordjevic, Branka
    V. Velickov, Asen
    Petrovic, Aleksandar
    Lazarevic, Milica
    Cvetkovic, Julija
    ARCHIVES OF BIOLOGICAL SCIENCES, 2023, 75 (02) : 141 - 154
  • [28] Effect of sakuranin on carbohydrate-metabolizing enzyme activity modifications in streptozotocin-nicotinamide-induced diabetic wistar rats
    Elsadek, Mohamed Farouk
    Ahmed, Badreldin Mohamed
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (03) : 1402 - 1406
  • [29] Amelioration of streptozotocin-induced type 2 diabetes mellitus in Wistar rats by arachidonic acid
    Gundala, Naveen K. V.
    Naidu, Vegi G. M.
    Das, Undurti N.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 496 (01) : 105 - 113
  • [30] Antidiabetic effect of bio-enhanced preparation of turmeric in streptozotocin-nicotinamide induced type 2 diabetic Wistar rats
    Sayeli, Vinay Kumar
    Shenoy, Ashok K.
    JOURNAL OF AYURVEDA AND INTEGRATIVE MEDICINE, 2021, 12 (03) : 474 - 479